A Phase 3 interventional study of aliskiren in Hypertension, sponsored by Novartis. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-07.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / HCTZ (300/320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg
6,689 studies on the registry are indexed under Hypertension; 964 are open to participants now.
This study's enrollment of 641 is above the median of 90 across 4,994 interventional studies indexed under Hypertension.
Browse Hypertension studies →Novartis is the lead sponsor of 703 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Other protocol-defined exclusion criteria may apply.
Change from baseline in diastolic blood pressure after 8 weeks
Change from baseline in systolic and diastolic blood pressure after 4 weeks and 8 weeks
Change from baseline in standing blood pressure after 4 weeks and 8 weeks
Achieve blood pressure control target of < 140/90 mmHg after 8 weeks
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis